Bright Minds Biosciences Receivables

Bright Minds Biosciences (DRUG) currently reports a receivables of $1.1M as of March 2026. That compares with $230K in the prior-year period — up 387.7% year over year. Use the charts on this page to explore Bright Minds Biosciences's receivables history and peer comparisons.

Bright Minds Biosciences's receivables increased from $230K to $1.1M — a 387.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bright Minds Biosciences reported $1.1M in receivables as of March 2026. That compares with $230K in the prior-year period — up 387.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bright Minds Biosciences, and consider following DRUG for alerts when major investors trade the stock.

Bright Minds Biosciences is classified in the Healthcare sector. On receivables, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRUG with unrelated industries.